H1-Antihistamines May No Longer Be Necessary for Patients With Refractory Chronic Spontaneous Urticaria After Initiation of Omalizumab

J Investig Allergol Clin Immunol. 2020 Apr 24;30(2):145-147. doi: 10.18176/jiaci.0464. Epub 2019 Nov 25.

Authors

L F Ensina^{1

2}, L K Arruda³, R A Campos⁴, R F Criado⁵, S Rodrigues Valle⁶, J Ml Melo³, J Cs Oliveira⁴, Jr Sd Dortas⁶, A P Cusato-Ensina¹, I C Camelo-Nunes², R C Agondi⁷

Affiliations

¹ CPAlpha Clinical Research Center, Barueri, Brazil.
² Federal University of São Paulo, São Paulo, Brazil.
³ Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
⁴ Federal University of Bahia, Salvador, Brazil.
⁵ Faculdade de Medicina do ABC, Santo André, Brazil.
⁶ Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
⁷ Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.

PMID: 31762438
DOI: 10.18176/jiaci.0464

No abstract available

Keywords: Histamine antagonists; Omalizumab; Therapeutics; Urticaria.

MeSH terms

Adult
Anti-Allergic Agents / therapeutic use*
Chronic Urticaria / drug therapy*
Female
Histamine H1 Antagonists / therapeutic use*
Humans
Male
Middle Aged
Omalizumab / therapeutic use*
Treatment Outcome

Substances

Anti-Allergic Agents
Histamine H1 Antagonists
Omalizumab